title: Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1.
abstract: BACKGROUND
  Hepatorenal syndrome type I (HRS I) may be a consequence of circulatory dysfunction in cirrhotic patients with portal hypertension. This uncontrolled interventional pilot study examines the hemodynamic and renal effects of large volume plasma expansion in HRS I.
  
  
  METHODS
  14 cirrhotic patients (8 m, 6 f, age 60 (58-65) years) with HRS I received large volume plasma expansion with up to 400 mL of 20% human albumin solution per 12 over 48 h under hemodynamic monitoring by transpulmonary thermodilution. Creatinine clearances (ClCreat) were calculated for 12-h periods. Plasma expansion was withheld if criteria of volume overload [Extravascular lung Water Index (ELWI) > 9 mL/kg or Global End-Diastolic Volume Index (GEDI) > 820 mL/m(2)] were met. Paracentesis was performed according to clinical necessity and treatment continued for 48 h thereafter. Serum creatinine values were observed for 12 days.
  
  
  RESULTS
  Patients received 1.6 (1.5-2.0) g of albumin per kg bodyweight and day for 48 to 96 h. During the treatment period, GEDVI [724 (643-751) mL/m(2) vs. 565 (488-719) mL/m(2) ; p = 0.001], cardiac index (CI) [4.9 (4.1-6.15) L/min/m(2) vs. 3.9 (3.4-5.0) L /min/m(2) ; p = 0.033], urinary output [25 (17-69) mL/h vs. 17 (8-39) mL/h; p = 0.016) and ClCreat [20 (15-47) vs. 12 (6-17); p = 0.006] increased whereas systemic vascular resistance index (SVRI), plasma renin activity (PRA) and plasma aldosterone were significantly reduced. At 48 h there were two complete responses (serum creatinine < 133 µmol/L) and on day 12, 8 patients had a complete response.
  
  
  CONCLUSIONS
  HRS I may respond to large volume plasma expansion with or without paracentesis.
authors.affiliation: II Medizinische Klinik, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22 D-81675 Munich, Germany. andreas.umgelter@lrz.tu-muenchen.de
authors.forename: Andreas
authors.initials: A
authors.lastname: Umgelter
authors.forename: Katrin S
authors.initials: KS
authors.lastname: Wagner
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Reindl
authors.forename: Peter B
authors.initials: PB
authors.lastname: Luppa
authors.forename: Fabian
authors.initials: F
authors.lastname: Geisler
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Huber
authors.forename: Roland M
authors.initials: RM
authors.lastname: Schmid
mesh_terms: D000368:Aged; D000418:Albumins / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006530:Hepatorenal Syndrome / Q000209:etiology / Q000628:therapy*; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications; D007668:Kidney / Q000187:drug effects; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D019152:Paracentesis; D010865:Pilot Projects; D010952:Plasma Substitutes / Q000627:therapeutic use*; D013815:Thermodilution; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000418:Albumins; D010952:Plasma Substitutes; D003404:Creatinine